Premature Infants
0
Pipeline Programs
5
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
AbbottABBOTT PARK, IL
1 programCompliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Sharp TherapeuticsSat75
Human BioSciencesH-HOPE Intervention
AbbottCompliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 -
Clinical Trials (3)
Total enrollment: 2,706 patients across 3 trials
Optimization of Saturation Targets And Resuscitation Trial (OptiSTART)
Start: Feb 2024Est. completion: Apr 2029700 patients
N/ARecruiting
Implementation of an Evidence Based Parentally Administered Intervention for Preterm Infants
Start: Nov 2020Est. completion: Nov 20241,882 patients
N/ACompleted
NCT01077271AbbottCompliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 -
Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA
Start: Oct 2008Est. completion: May 2011124 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 2,706 patients
5 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.